Notice2024-13449

Foreign-Trade Zone (FTZ) 230, Notification of Proposed Production Activity; Patheon Softgels; (Pharmaceutical Products); High Point, North Carolina

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
June 20, 2024

Issuing agencies

Commerce DepartmentForeign-Trade Zones Board

Full Text

<html>
<head>
<title>Federal Register, Volume 89 Issue 119 (Thursday, June 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 119 (Thursday, June 20, 2024)]
[Notices]
[Page 51873]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-13449]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-31-2024]


Foreign-Trade Zone (FTZ) 230, Notification of Proposed Production 
Activity; Patheon Softgels; (Pharmaceutical Products); High Point, 
North Carolina

    The Piedmont Triad Partnership, grantee of FTZ 230, submitted a 
notification of proposed production activity to the FTZ Board (the 
Board) on behalf of Patheon Softgels (Patheon), for Patheon's facility 
in High Point, North Carolina within Subzone 230C. The notification 
conforming to the requirements of the Board's regulations (15 CFR 
400.22) was received on June 12, 2024.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished 
product(s) and material(s)/component(s) would be added to the 
production authority that the Board previously approved for the 
operation, as reflected on the Board's website.
    The proposed finished products include CU06-1004 and northenindrone 
acetate (duty-free).
    The proposed foreign-status materials/components include: CU06-
1004(active pharmaceutical ingredient); titanium dioxide (35%); mono 
diglycerides; surfactants; glycerol monolinoneate; red iron oxide; 
yellow iron oxide; medium chain triglycerides; vitamin E; sesame oil 
nf; linoleoyl polyoxyl-6 glycerides; ethinylestradiol micronized; 
glycerin and northenindrone acetate (active pharmaceutical ingredient) 
(duty rate ranges from duty-free to 6.5%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
<a href="/cdn-cgi/l/email-protection#caacbeb08abeb8abaeafe4ada5bc"><span class="__cf_email__" data-cfemail="9ef8eae4deeaecfffafbb0f9f1e8">[email&#160;protected]</span></a>. The closing period for their receipt is July 30, 2024.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Kolade Osho at 
<a href="/cdn-cgi/l/email-protection#4b0024272a2f2e65043823240b3f392a2f2e652c243d"><span class="__cf_email__" data-cfemail="58133734393c3d76172b3037182c2a393c3d763f372e">[email&#160;protected]</span></a>.

    Dated: June 13, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-13449 Filed 6-18-24; 8:45 am]
BILLING CODE 3510-DS-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on June 20, 2024.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.